R.H. Bluestein & Co’s AbbVie ABBV Stock Holding History

R.H. Bluestein & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$822K	Buy	6,125 +500	+9%	+$71.7K	0.05%	104
2022 Q2	$862K	Buy	5,625 +350	+7%	+$53.5K	0.05%	111
2022 Q1	$855K	Hold	5,275	–	–	0.04%	120
2021 Q4	$714K	Hold	5,275	–	–	0.03%	159
2021 Q3	$569K	Hold	5,275	–	–	0.02%	200
2021 Q2	$594K	Sell	5,275 -500	-9%	-$56.3K	0.02%	202
2021 Q1	$625K	Sell	5,775 -507	-8%	-$54.2K	0.03%	173
2020 Q4	$673K	Buy	6,282 +2,507	+66%	+$241K	0.03%	143
2020 Q3	$331K	Sell	3,775 -37	-1%	-$3.48K	0.02%	230
2020 Q2	$374K	Buy	3,812 +658	+21%	+$57.9K	0.02%	189
2020 Q1	$240K	Buy	3,154 +420	+15%	+$35.8K	0.02%	223
2019 Q4	$242K	Buy	+2,734	New	+$227K	0.01%	309
2019 Q3	–	Sell	-3,850	Closed	-$280K	–	329
2019 Q2	$280K	Buy	+3,850	New	+$303K	0.01%	252
2018 Q4	–	Sell	-4,555	Closed	-$431K	–	285
2018 Q3	$431K	Buy	4,555 +700	+18%	+$66.4K	0.02%	194
2018 Q2	$357K	Buy	3,855 +1,100	+40%	+$107K	0.02%	205
2018 Q1	$261K	Buy	+2,755	New	+$303K	0.01%	272
2015 Q1	–	Sell	-3,550	Closed	-$232K	–	341
2014 Q4	$232K	Buy	+3,550	New	+$224K	0.01%	315

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

R.H. Bluestein & Co's ABBV Position: Q3 2022 in Review

R.H. Bluestein & Co increased its AbbVie (ABBV) stake by 8.9% in Q3 2022, buying an estimated $71.7K and bringing the position to 6,125 shares worth $822K. The position accounts for 0.05% of the portfolio, ranked #104.

R.H. Bluestein & Co first reported a position in ABBV in Q4 2014 and has held it in 17 quarters since. The position peaked at $862K in Q2 2022. 2,968 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.

R.H. Bluestein & Co held 6,125 shares of AbbVie worth $822K as of Q3 2022.
R.H. Bluestein & Co bought 500 AbbVie shares in Q3 2022, an estimated $71.7K.
AbbVie made up 0.05% of R.H. Bluestein & Co's portfolio in Q3 2022, its #104 holding.
R.H. Bluestein & Co first reported a position in AbbVie in Q4 2014 and has held it in 17 quarters since.
R.H. Bluestein & Co's AbbVie position peaked at $862K in Q2 2022.
2,968 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.

Based on R.H. Bluestein & Co's 13F filing for Q3 2022, filed 14 Nov 2022.